Analysts Offer Predictions for GH Research FY2024 Earnings

GH Research PLC (NASDAQ:GHRS) – HC Wainwright lowered their FY2024 earnings estimates for shares of GH Research in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.80) for the year, down from their previous estimate of ($0.76). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for GH Research’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.49) EPS.

Separately, Canaccord Genuity Group reduced their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th.

GH Research Stock Up 7.8 %

Shares of GHRS stock opened at $9.50 on Wednesday. GH Research has a 12-month low of $6.00 and a 12-month high of $14.99. The firm has a fifty day moving average of $8.41 and a 200-day moving average of $8.92. The company has a market capitalization of $494.29 million, a price-to-earnings ratio of -12.03 and a beta of 0.84.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. lifted its holdings in GH Research PLC (NASDAQ:GHRS) by 1.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).